Picture of Celltrion Healthcare Co logo

091990 — Celltrion Healthcare Co News Story

0.000.00%
kr flag iconLast trade - 00:00
HealthcareAdventurousLarge Cap

EU regulator okays COVID-19 treatments from GSK-Vir and Sobi (updated)

(Adds detail from EMA statement, background)
    Dec 16 (Reuters) - The European Union's drug regulator on
Thursday approved a COVID-19 treatment from British-U.S. duo GSK
 GSK.L  and Vir Biotechnology  VIR.O  and another from Swedish
drugmaker Sobi  SOBIV.ST , as the bloc builds its defences
against Omicron.            
    The approval by the European Medicines Agency (EMA) of
GSK-Vir's antibody drug sotrovimab and Sobi's arthritis drug
Kineret  come as governments struggle with soaring infections
and worry about the swiftly-spreading Omicron variant of the
coronavirus.
    The European Union's public health body warned on Wednesday
that there was a "very high" risk Omicron would become dominant
in Europe by early next year.  urn:newsml:reuters.com:*:nL1N2T01DJ
    EMA's human medicines committee recommended using Kineret to
treat COVID-19 in adults with pneumonia requiring oxygen support
and those who were at risk of developing severe respiratory
failure.
    GSK-Vir's sotrovimab, branded Xevudy, was recommended for
treating adults and adolescents who did not require oxygen
support but were at a higher risk their disease would worsen. 
    Final and formal approvals are up to the European
Commission, which typically endorses EMA recommendations.
    

    <^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
Omicron set to be Europe's dominant variant by early 2022 - ECDC
    urn:newsml:reuters.com:*:nL1N2T01DJ
COVID SCIENCE-Omicron thrives in airways, not lungs; new data on
asymptomatic cases     urn:newsml:reuters.com:*:nL1N2T02CQ
FACTBOX-Front runners in development of antibody drugs against
COVID-19     urn:newsml:reuters.com:*:nL8N2R81NW
FACTBOX-What COVID-19 vaccine and drug makers have to say about
Omicron     urn:newsml:reuters.com:*:nL4N2SN31Z
    ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>
 (Reporting by Pushkala Aripaka and Amna Karimi in Bengaluru;
Editing by Edmund Blair)
 ((Amna.Karimi@thomsonreuters.com;))

Recent news on Celltrion Healthcare Co

See all news